ImportanceKnowledge about the prevalence and tumor types of CDKN2A-related melanoma-astrocytoma syndrome (MAS) is limited and could improve disease recognition.ObjectiveTo estimate the prevalence and describe the tumor types of MAS.Design, Setting, and ParticipantsThis retrospective cohort study analyzed all available MAS cases from medical centers in the US (2 sites) and Europe (2 sites) and from biomedical population genomic databases (UK Biobank [United Kingdom], Geisinger MyCode [US]) between January 1, 1976, and December 31, 2020. Patients with MAS with CDKN2A germline pathogenic variants and 1 or more neural tumors were included. Data were analyzed from June 1, 2022, to January 31, 2023.Main Outcomes and MeasuresDisease prevalence and tumor frequency.ResultsPrevalence of MAS ranged from 1 in 170 503 (n = 1 case; 95% CI, 1:30 098-1:965 887) in Geisinger MyCode (n = 170 503; mean [SD] age, 58.9 [19.1] years; 60.6% women; 96.2% White) to 1 in 39 149 (n = 12 cases; 95% CI, 1:22 396-1:68 434) in UK Biobank (n = 469 789; mean [SD] age, 70.0 [8.0] years; 54.2% women; 94.8% White). Among UK Biobank patients with MAS (n = 12) identified using an unbiased genomic ascertainment approach, brain neoplasms (4 of 12, 33%; 1 glioblastoma, 1 gliosarcoma, 1 astrocytoma, 1 unspecified type) and schwannomas (3 of 12, 25%) were the most common malignant and benign neural tumors, while cutaneous melanoma (2 of 12, 17%) and head and neck squamous cell carcinoma (2 of 12, 17%) were the most common nonneural malignant neoplasms. In a separate case series of 14 patients with MAS from the US and Europe, brain neoplasms (4 of 14, 29%; 2 glioblastomas, 2 unspecified type) and malignant peripheral nerve sheath tumor (2 of 14, 14%) were the most common neural cancers, while cutaneous melanoma (4 of 14, 29%) and sarcomas (2 of 14, 14%; 1 liposarcoma, 1 unspecified type) were the most common nonneural cancers. Cutaneous neurofibromas (7 of 14, 50%) and schwannomas (2 of 14, 14%) were also common. In 1 US family, a father and son with MAS had clinical diagnoses of neurofibromatosis type 1 (NF1). Genetic testing of the son detected a pathogenic CDKN2A splicing variant (c.151-1G>C) and was negative for NF1 genetic alterations. In UK Biobank, 2 in 150 (1.3%) individuals with clinical NF1 diagnoses had likely pathogenic variants in CDKN2A, including 1 individual with no detected variants in the NF1 gene.Conclusions and RelevanceThis cohort study estimates the prevalence and describes the tumors of MAS. Additional studies are needed in genetically diverse populations to further define population prevalence and disease phenotypes.
Hereditary endocrine tumor syndromes (ETS) including Multiple Endocrine Neoplasia Types 1 and 2 (MEN1 and MEN2), von Hippel-Lindau (VHL), and Hereditary Paraganglioma and Pheochromocytoma syndromes (PGL/PCC) have a collective prevalence of 1 in 8500. In current practice, patients’ personal and family histories are used to determine whether genetic testing for ETS is warranted. Population genetic screening for other actionable conditions implies that current practice can be enhanced to identify individuals with genetic variants and that identification of such individuals can lead to improvements in risk management and early-onset diagnoses. It is unknown whether such benefits occur when screening for ETS risk. We report on the rate of syndrome-related features and post-disclosure risk management in patients informed of a pathogenic/likely pathogenic (P/LP) variant in a gene associated with an ETS through the MyCode Community Health Initiative (MyCode). MyCode is a biobank of individuals from a health system who consent to health-related research and return of clinically actionable results. Exome sequences are analyzed for P/LP variants in actionable genes, confirmed by a clinical laboratory, and disclosed to participants and their providers. All participants are offered follow-up with a genetics provider post-disclosure. Here, we focus on participants that received a P/LP variant in MEN1, RET, VHL, or an SDHx gene from June 2016-October 2019. From May-July 2020 we performed dual, manual review of participants’ electronic health records to assess personal and family histories, risk management behaviors, and post-disclosure diagnoses of endocrine neoplasms. Of 87,493 participants with available exome data, P/LP variants in genes of interest were identified in and disclosed to 80 participants (65% female, 99% self-reported White race, 99% self-reported non-Hispanic ethnicity, median age 57 years at results disclosure, median time since disclosure 2 years). Eighty-one percent of participants (n=65) did not have a prior diagnosis of an ETS and were included in additional analyses. Five participants (8%) had a personal history of syndrome-related features; 16 (25%) had a positive family history. Only seven (11%) met existing clinical testing criteria pre-disclosure. Post-disclosure, 37 (57%) completed at least one recommended risk management behavior; 11 of these (17%) were diagnosed with a syndrome-related neoplasm (e.g., medullary thyroid cancer). Results of population screening in a healthcare cohort suggest genetic variants associated with ETS risk are more common than previously reported (1 in 1094). Though additional studies on clinical utility are needed, these results suggest that screening healthcare populations for genetic risk can enable detection of individuals at risk for ETS, lead to uptake of risk management, and facilitate relevant clinical diagnoses.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.